FDA Advisory Committee Backs Novartis’ SigniforR

by Kathy Jones on  November 8, 2012 at 8:12 PM Drug News
RSS Email Print This Page Comment
Font : A-A+

An advisory committee for the US Food and Drug Administration has unanimously recommended that the health regulator approve Novartis' SigniforR drug for treating Cushing's disease patients who require medical therapeutic intervention.
 FDA Advisory Committee Backs Novartis’ SigniforR
FDA Advisory Committee Backs Novartis’ SigniforR

FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) said that it has based its recommendation following the results of various studies, including PASPORT-CUSHINGS, which revealed that the drug rapidly reduced the mean urinary-free cortisol (UFC), the key measure of biochemical control of the disease.

The committee also acknowledged that the drug led to hyperglycemia and elevations in liver enzymes in the patients but said that lack of other therapies for treating the condition means that the benefits outweighed the side effects. "In spite of significant concerns about hyperglycemia and uncontrolled diabetes, I think it's very highly probable that those glucose levels can be adequately controlled with available medications for managing diabetes, including insulin", Brown University's Robert Smith, who was part of the panel, said.


Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive